PREPS and L-particles: A new approach to virus-like particle vaccines

Expert Review of Vaccines

Volumn 1, Issue 4, 2002, Pages 427-432

  Pardoe, Ian ^a   Dargan, Derrick ^b  

^a Henderson Morley Plc   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

herpesviruses; Herpes simplex; L particle; PREPS; Protein delivery sector virus like particles; Vaccine; Virus vector

Indexed keywords

RECOMBINANT PROTEIN; VACCINE; VIRUS DNA;

ARTICLE; CANCER; DNA SYNTHESIS; HERPES SIMPLEX VIRUS 1; L PARTICLE; NONHUMAN; PREVIRAL DNA REPLICATION ENVELOPED PARTICLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; VIRION; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS NUCLEOCAPSID; VIRUS PARTICLE;

DNA, VIRAL; HERPESVIRUS 1, HUMAN; HUMANS; VIRAL PROTEINS; VIRAL VACCINES; VIRUSES;

EID: 0038329318     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.4.427     Document Type: Article

References (29)

1. Boisgerault F et al. Virus-like particles: a new family of delivery systems. Expert Rev. Vaccines 1(1) 101-109 (2002).
2. Breitburd F et al. Human papillomavirus vaccines. Cancer Biology 9, 431-445 (1999).
3. Evans TG et al. Phase 1 study of a recombinant VLP vaccine against HPV 11 in healthy adult volunteers. J. Infect. Dis. 183, 1485-1493 (2001).
4. Sedlik C et al. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T-cells. Proc. Natl Acad Sci. USA 94 (14), 7503-7508 (1997).
5. Greenstone HL et al. Chimeric papillomavirus virus like particles elicit antitumour immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl Acad. Sci. USA 95 (4), 1800-1805 (1998).
6. nd Edition. Fields BN, Knipe DM, Howley PM et al. (Eds), Lippincott-Raven, Philadelphia, PA, USA (1996).
7. Szilagyi JF, Cunningham C. Identification and Characterization of a novel non-infectious herpes simplex virus related particle. J. Gen. Virol. 72, 661-668 (1991).
8. Stevens AC, Spear, PG. Herpesvirus capsid assembly and envelopment. In: Structural Biology of Viruses. Chui W, Burnett RM, Garcea RL (Eds). Oxford University Press, UK, 312-351 (1997).
9. McLaughlan J, Rixon F. Characterization of enveloped tegument structures (L Particles) produced by alpha herpes viruses: integrity of the tegument does not depend on the presence of capsid or envelope. J. Gen. Virol. 73, 269-276 (1992).
10. Dargan DJ, Patel A, Subak-Sharpe JH. PREPS: Herpes simplex virus Type 1 specific particles produced by infected cells when viral DNA replication is blocked. J. Virol. 69, 4924-4932 (1995).
11. Rixon FJ, Addison C, McLauchlan J. Assembly of enveloped tegument structures (L particles) can occur independently of virion maturation in herpes simplex virus Type 1-infected cells. J. Gen. Virol. 73, 277-284 (1992).
12. McLauchlan J, Addison C, Craigie M, Rixon F. Non-infectious L particles supply functions which can facilitate infection by HSV-1. Virology 190, 682-688(1992).
13. Dargan DJ, Subak-Sharpe JH. The effect of herpes simplex virus Type 1 L-particles on virus entry, replication and the infectivity of naked herpesvirus DNA. Virology 239, 378-388 (1997).
14. Zhang Y, McKnight JLC. Herpes simplex virus Type 1 UL46 and UL47 deletion mutants lack VP11 and VP12 or VP13 and VP14 respectively and exhibit altered viral thymidine kinase expression J. Virol. 67, 1482-1492 (1993).
15. Subak-Sharpe JH, Dargan DJ. HSV molecular biology; general aspects of herpes simplex virus molecular biology. J. Virus Genes 16 (3), 239-251 (1998).
16. Fruh K, Ahn K, Djaballah H et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 375, 415-418 (1995).
17. Boursnell ME, Entsile C, Blakeley D et al. A genetically inativated herpes simplex virus Type 2 (HSV2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J. Infect. Dis. 170, 1100-1109 (1994).
18. Andrew ME. Protective efficacy of a recombinant vaccinia virus in vaccinia-immune mice. Immunol. Cell Biol. 67, 339-341 (1989).
19. Papp Z, Babiuk LA, Baca-Estrada ME. The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoproteinD of bovine herpes Type 1. Vaccine 17, 933-943 (1999).
20. Schlesinger S. Alphavirus vectors: development and potential therapeutic applications. Expert Opin. Biol. Ther. 1(2), 177-191 (2001).
21. Mandl S et al. Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors. J. Virol. 75(2), 622-627 (2001).
22. Belyakov IM, Moss B, Strober W, Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl Acad. Sci. USA 96, 4512-4517 (1999).
23. Irvine KR et al. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl Cancer Inst. 89 (21), 1595-1601 (1997).
24. Kundig TM, Kalberer CP, Hengartner H, Zinkernagel RM. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 11, 1154-1158 (1993).
25. Lambright ES et al. Effect of preexisting antiherpes immunity on the efficacy of herpes simplex viral therapy in a murine ip. tumor model. Mol. Ther. 2 (4), 387-393 (2000).
26. Chahlavi A et al. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. 6(10), 1751-1758 (1999).
27. Delman KA et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum. Gene Ther. 11(18), 2465-2472 (2000).
28. Brockman MA et al. Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J. Virol. 76 (8), 3678-3687 (2002).
29. Lenz P, Day PM, Pang YY et al. Papillomavirus-like particles with immune cells. Int. Immunol. 13(5), 633-641 (2001).